Loading…
NextCure, Inc. is projected to decline to $4.14 by 2027, a -6% move from its current price of $4.40. NXTC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $4.03 | $4.40 | $4.81 | -0.01% |
| Aug 6 | $3.88 | $4.40 | $4.98 | -0.02% |
| Aug 7 | $3.78 | $4.40 | $5.13 | -0.02% |
| Aug 8 | $3.69 | $4.40 | $5.25 | -0.03% |
| Aug 9 | $3.61 | $4.40 | $5.36 | -0.04% |
| Aug 10 | $3.54 | $4.40 | $5.46 | -0.05% |
| Aug 11 | $3.48 | $4.40 | $5.55 | -0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.48 | $4.40 | $5.55 | -0.06% |
| Week 2 | $3.16 | $4.40 | $6.12 | -0.11% |
| Week 3 | $2.93 | $4.39 | $6.58 | -0.17% |
| Week 4 | $2.75 | $4.39 | $7.00 | -0.22% |
| Week 5 | $2.60 | $4.39 | $7.40 | -0.28% |
| Week 6 | $2.47 | $4.39 | $7.77 | -0.33% |
| Week 7 | $2.36 | $4.38 | $8.13 | -0.39% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures.
The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NXTC is NextCure, Inc. Its stock trades with a current price of $4.15 and a market capitalization of $16.87M, ranking it at 4922 by market cap. The stock sits in a niche healthcare/biopharma space and has a diverse early-stage pipeline focused on cancer and other diseases.
The price outlook shows variability across years, with the near term relatively flat and longer horizons offering both downside risk and potential upside. The 30-year forecasted path includes periods of bear and bull momentum, culminating in a bullish stance by 2040 and extending into 2050.
A major floor 63.6% below — a decisive break under it would weaken the trend.
The nearest floor, 63.6% below — buyers have tended to step in here.
The nearest ceiling, 50.7% above — a clean break opens room to run.
A major ceiling 190.2% above — clearing it would confirm fresh momentum.
Key NXTC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NXTC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.95 | Sell | $4.72 | Sell |
| MA 10 | $4.81 | Sell | $4.71 | Sell |
| MA 20 | $4.26 | Buy | $4.37 | Buy |
| MA 50 | $3.81 | Buy | $4.79 | Sell |
| MA 100 | $7.27 | Sell | $6.38 | Sell |
| MA 200 | $9.50 | Sell | $7.81 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.82 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -5.51 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | -37.48 | Sell |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 1.67 | Buy |
| Awesome (5,34) | 1.67 | Buy |
| Ultimate (7,14,28) | 51.85 | Neutral |
| Momentum (10) | -1.84 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 4.98 | Sell |
| ADX (14) | 27.02 | Sell |
| ATR (14) | 0.45 | Info |
Technically, the near term picture is neutral. The RSI14 is 50, signaling balanced momentum around the midline. The 50-day simple moving average sits at $3.81, while the 200-day simple moving average sits at $9.50, illustrating a wider long-term gap to prevailing price action.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.60 | $4.40 | $6.17 | 0% | Neutral | |
| $3.02 | $4.14 | $6.14 | -6% | Neutral | |
| $2.88 | $4.20 | $6.65 | -5% | Neutral | |
| $2.09 | $3.22 | $5.36 | -27% | Bearish | |
| $2.15 | $3.46 | $5.99 | -21% | Bearish | |
| $3.09 | $5.22 | $9.35 | +19% | Neutral | |
| $2.85 | $5.02 | $9.28 | +14% | Neutral | |
| $2.77 | $5.08 | $9.65 | +15% | Neutral | |
| $2.72 | $5.18 | $10.10 | +18% | Neutral | |
| $2.14 | $4.25 | $8.47 | -3% | Neutral | |
| $2.81 | $6.24 | $13.69 | +42% | Bullish | |
| $5.93 | $13.18 | $30.31 | +200% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.60 | $4.40 | $5.30 | +0.00% |
| September 2026 | $3.39 | $4.12 | $5.23 | -6.30% |
| October 2026 | $3.54 | $4.37 | $5.65 | +5.96% |
| November 2026 | $3.74 | $4.67 | $6.14 | +6.81% |
| December 2026 | $3.67 | $4.62 | $6.17 | -0.93% |
Click any year to see its month-by-month NXTC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
NextCure, Inc.'s 2026 outlook centres on $4.40, within a $1.60 to $6.17 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, NXTC could reach as high as $6.14, with a base case around $4.14 and support toward $3.02 — roughly -6% from $4.40. A consolidation phase looks the most probable path here.
Expect NXTC to range from $2.88 to $6.65 through 2028. The $4.20 average target implies a -5% move from current prices. That is up +1% on the projected 2027 average. Price action looks broadly range-bound.
The NXTC price prediction for 2029 points to an average of $3.22 (low $2.09, high $5.36) — a potential decline of -27% on today's $4.40. Expect choppier, lower action through this leg of the cycle.
In 2030, NXTC is projected to trade between $2.15 and $5.99, averaging $3.46 — a potential decline of -21% from today's $4.40. That is up +7% on the projected 2029 average. A cyclical pullback looks likely — prices rarely move in a straight line.
NextCure, Inc.'s 2031 outlook centres on $5.22, within a $3.09 to $9.35 range. That is up +51% on the projected 2030 average. That marks a +19% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, NXTC could reach as high as $9.28, with a base case around $5.02 and support toward $2.85 — roughly +14% from $4.40. Price action looks broadly range-bound.
Expect NXTC to range from $2.77 to $9.65 through 2033. The $5.08 average target implies a +15% move from current prices. That is up +1% on the projected 2032 average. A consolidation phase looks the most probable path here.
The NXTC price prediction for 2034 points to an average of $5.18 (low $2.72, high $10.10) — a potential gain of +18% on today's $4.40. Price action looks broadly range-bound.
In 2035, NXTC is projected to trade between $2.14 and $8.47, averaging $4.25 — a potential decline of -3% from today's $4.40. That is -18% versus the projected 2034 average. A consolidation phase looks the most probable path here.
NextCure, Inc.'s 2040 outlook centres on $6.24, within a $2.81 to $13.69 range. That is up +47% on the projected 2035 average. That marks a +42% change versus current levels. Momentum favours further upside here.
By 2050, NXTC could reach as high as $30.31, with a base case around $13.18 and support toward $5.93 — roughly +200% from $4.40. Buyers look set to stay in control over this stretch.
Investing $1,000 in NXTC today (≈ 227.272727 NXTC) could be worth
$2,995.45
+$1,995.45 (+200%) by 2050 · US Dollar
Based on the average projected NXTC price of $13.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NXTCwould be worth at today's price.
$1,000 invested in NXTC on Jul 31, 2025 (≈ 201.612902 NXTC) would be worth
$887.1
-$112.9 (-11.3%) today · 0.89× · US Dollar
Based on a NXTC entry price of $4.96 vs. today's $4.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.24 | $1,037.74 | +3.8% |
| 1 month ago | $1.95 | $2,256.41 | +125.6% |
| 3 months ago | $9.36 | $470.09 | -53.0% |
| 6 months ago | $10.93 | $402.56 | -59.7% |
| 1 year ago | $4.96 | $887.1 | -11.3% |
| All time (5.0y) ago | $90.24 | $48.76 | -95.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NXTC forecast.
Our base-case forecast reaches $8.80 around 2050.
Implied market cap at $8.80: $35.81M
The multi-year forecast points to a mixed trajectory with meaningful upside later in the decade. In 2026, the average price is expected to be $4.15 with 0% ROI. In 2029 the average is $3.03 and the outlook turns bearish with a -26.9% ROI in the max scenario.
By 2030 the average is $3.27 with a -21.1% ROI and a bearish sentiment. The forecast turns more constructive by 2031–2034, where the averages range from $4.92 to $4.89 with single- to low-double-digit positive ROIs. A notable bullish shift appears by 2040, with an average of $5.88 and a 41.8% ROI, and the bullish tone extends to 2050, where the average reaches $12.42 and the max scenario shows a 28.57 price with a 199.7% ROI.
These numbers reflect a long-run risk/reward profile tied to the health biotech sector and early-stage clinical programs.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $3.27 with a -21.1% ROI and a bearish sentiment.
Forecasts show a mix of risks and potential. Near term could be flat or lower (e.g., 2029 average $3.03, ROI -26.9%), while longer term shows a bullish path with an average of $12.42 by 2050 and a max ROI of 199.7%.
The forecasted path includes higher prices later in the horizon, with 2040 average $5.88 and 2050 average $12.42; the maximums in the series reach $12.89 in 2040 and $28.57 in 2050, indicating possible breach of $10 in the later years.
Near term risks are shown by bearish readings in 2029-2030, with 2029 max $5.04 and 2030 max $5.66 and negative ROIs (e.g., -26.9% in 2029, -21.1% in 2030). These reflect volatility common to early-stage biopharma equities.
NXTC is currently priced at $4.15 with a market capitalization of $16.87M and a market rank of 4922.
NextCure, Inc. Community Discussion
0Share your NextCure, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.